Literature DB >> 20356458

CMTM5-v1, a four-transmembrane protein, presents a secreted form released via a vesicle-mediated secretory pathway.

Henan Li1, Xiaohuan Guo, Luning Shao, Markus Plate, Xiaoning Mo, Yu Wang, Wenling Han.   

Abstract

The CKLF-like MARVEL transmembrane domain-containing family (CMTM) is a novel family of proteins linking classical chemokines and the transmembrane 4 superfamily (TM4SF). Our earlier studies indicated several CMTM members (such as CKLF1 and CMTM2) have a secreted form. This is the first report of the secreted form of CMTM5-v1, the major RNA splicing form of CMTM5, which is produced as small vesicles (100 nm diameter) and floats at a peak density of 1.19 g/ml on continuous sucrose gradients. CMTM5-v1 has no obvious co-localization with CD63 or Golgi complex. In addition, brefeldin A but not wortmannin can inhibit the secretion of CMTM5-v1. Our results suggest that CMTM5-v1 might be secreted via a different vesicle-mediated secretory pathway, which will be helpful for the studies of vesicle-mediated secretion and MARVEL domain-containing proteins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20356458     DOI: 10.5483/bmbrep.2010.43.3.182

Source DB:  PubMed          Journal:  BMB Rep        ISSN: 1976-6696            Impact factor:   4.778


  10 in total

1.  CMTM3 presents a secreted form released via exosomes.

Authors:  Baocai Liu; Henan Li; Weiwei Fu; Yingying Cheng; Wanqiong Yuan; Wanchang Liu; Hui Xue; Xiaoning Mo
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-04-28       Impact factor: 3.848

2.  The Secreted Form of Transmembrane Protein 98 Promotes the Differentiation of T Helper 1 Cells.

Authors:  Weiwei Fu; Yingying Cheng; Yanfei Zhang; Xiaoning Mo; Ting Li; Yuanfeng Liu; Pingzhang Wang; Wen Pan; Yingyu Chen; Yintong Xue; Dalong Ma; Yu Zhang; Wenling Han
Journal:  J Interferon Cytokine Res       Date:  2015-05-06       Impact factor: 2.607

3.  [Association of CMTM5 gene expression with the risk of in-stent restenosis in patients with coronary artery disease after drug-eluting stent implantation and the effects and mechanisms of CMTM5 on human vascular endothelial cells].

Authors:  T F Liu; T Lin; L H Ren; G P Li; J J Peng
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-10-18

4.  [Association between CMTM5 gene and coronary artery disease and the relative mechanism].

Authors:  T F Liu; T Lin; L H Ren; G P Li; J J Peng
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-18

Review 5.  CMTM family proteins 1-8: roles in cancer biological processes and potential clinical value.

Authors:  Jie Wu; Lan Li; Siyi Wu; Bin Xu
Journal:  Cancer Biol Med       Date:  2020-08-15       Impact factor: 4.248

6.  CMTM5-v1 inhibits cell proliferation and migration by downregulating oncogenic EGFR signaling in prostate cancer cells.

Authors:  Yeqing Yuan; Zhengzuo Sheng; Zhenhua Liu; Xiaowei Zhang; Yunbei Xiao; Jing Xie; Yixiang Zhang; Tao Xu
Journal:  J Cancer       Date:  2020-04-06       Impact factor: 4.207

Review 7.  Chemokine-Like Factor-Like MARVEL Transmembrane Domain-Containing Family in Hepatocellular Carcinoma: Latest Advances.

Authors:  Mengxia Li; Fangzhou Luo; Xinyao Tian; Shengyong Yin; Lin Zhou; Shusen Zheng
Journal:  Front Oncol       Date:  2020-11-13       Impact factor: 6.244

8.  CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway.

Authors:  Linjin Li; Yiren Hu; Dake Chen; Jianlong Zhu; Wenshuo Bao; Xiaomin Xu; Heyi Chen; Wu Chen; Rui Feng
Journal:  Mol Med Rep       Date:  2021-11-18       Impact factor: 2.952

9.  CMTM5 is downregulated and suppresses tumour growth in hepatocellular carcinoma through regulating PI3K-AKT signalling.

Authors:  Gang Xu; Chengxue Dang
Journal:  Cancer Cell Int       Date:  2017-11-29       Impact factor: 5.722

Review 10.  Research Advances in CKLF-like MARVEL Transmembrane Domain-containing Family in Non-small Cell Lung Cancer.

Authors:  Keheng Wu; Xiaoman Li; Huadi Gu; Qiao Yang; Yingying Liu; Liang Wang
Journal:  Int J Biol Sci       Date:  2019-09-07       Impact factor: 6.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.